The impact of non-structured PSA testing on prostate cancer-specific mortality on New Zealand Maori men.

ABSTRACT:

Objectives

To assess the impact of differences in Prostate-Specific Antigen (PSA) testing rates on prostate cancer (PCa) diagnosis and PCa-specific mortality among Māori men in a New Zealand (NZ) population.

Patients and methods

Māori men aged 40 years or older, without a history of PCa, with a PSA test between 2006 and 2018 were included. The cohort was divided into two groups; the "screened group" (ScG) consisting of men who had at least one PSA test every four years or less, and the "non-screened group" (non-SG). We measured the rate of cancer diagnoses and used competing risk analysis to assess survival.

Results

The study cohort included 63,939 Māori men, with 37,048 (58%) in the ScG. PCa was more frequently diagnosed in the ScG (3.7% vs. 3.0%, P < 0.001). A highe

SUBMITTER: Matti B 

PROVIDER: S-EPMC11449978 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature